We use cookies for a better user experience. Read our Privacy Policy

I Agree

Chronic Inducible Urticaria Therapeutics Market

Chronic Inducible Urticaria Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Chronic Inducible Urticaria Therapeutics: Introduction

  • Urticaria is a disease characterized by the development of hives, angioedema (swelling), or both at once. It affects about 20% of people at some point in their lives. Angioedema is a form of urticaria, wherein the swelling is caused by edema in deeper dermal, cutaneous, and sub-mucosal tissue. There are two types of urticaria: short lived (acute) and long term (chronic). According to the current European guidelines, chronic urticaria is divided into chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU). Chronic urticaria occurs daily for more than six weeks, while acute urticaria is present for less than six weeks. Chronic inducible urticaria encompasses various chronic urticaria subtypes caused by specific triggers.
  • The treatment of chronic inducible urticaria starts with physical examination, followed by various histopathological tests. Non-sedating oral antihistamines is the first line of treatment for acute and chronic urticaria due to their lack of anticholinergic and central nervous system effects. In chronic inducible urticaria, montelukast is the first line of treatment and a preferred combination agent with leukotrienes. Tricyclic antidepressants such as doxepin, leukotrienes receptor antagonists, sulfonamide, and glucocorticoids are the second line of treatment for chronic urticaria. There is no specific test for the diagnosis of urticaria. However, a skin test is helpful to determine the substances responsible for the allergy. Blood tests are conducted regularly to diagnose the systemic illness that is caused due to histamine release.

Key Drivers and Restraints of Global Chronic Inducible Urticaria Therapeutics Market

  • Advancements in therapy, launch of new biologic products, and constant innovation and research in chronic inducible urticaria treatment are expected to drive the global chronic inducible urticaria therapeutics market during the forecast period. Development of novel targeted therapies, such as omalizumab for the management of chronic urticarial, is anticipated to propel the market in the near future. A study was conducted in Poland on 1091 patients suffering from chronic urticaria in order to assess the epidemiology and clinical characteristics of chronic urticaria in 2019. It was reported that chronic spontaneous urticaria is about twice as frequent cause of chronic urticaria as compared to chronic inducible urticaria.
  • Increase in awareness about hypersensitivity is boosting the demand for chronic inducible urticaria treatment. Patients are now more pro-active about their health and are willing to seek physician's advice at an early stage. Rise in literacy rate plays a significant role in general awareness among patients for managing chronic inducible urticaria. Besides, rise in per capita disposable income is encouraging people to spend freely on health care facilities, thus contributing to the growth of the chronic inducible urticaria therapeutics market.

North America to Lead Global Chronic Inducible Urticaria Therapeutics Market

  • In terms of region, the global chronic inducible urticaria therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are likely to account for major share of the global chronic inducible urticaria therapeutics market during the forecast period, owing to developed health care infrastructure, large patient population, and increase in technological developments in these regions. According to the American Academy of Allergy, Asthma and Immunology, nearly 20% of the people in the U.S. are afflicted with chronic urticaria. Additionally, launch of novel therapies such as omalizumab and rise in awareness about allergies are expected to drive the market during the forecast period.
  • Europe is expected to constitute large share of the global chronic inducible urticaria therapeutics market during the forecast period due to rise in prevalence of chronic urticaria and availability of new medications in the region

Key Players Operating in Global Chronic Inducible Urticaria Therapeutics Market

  • The global chronic inducible urticaria therapeutics market is fragmented, with the presence of large numbers of small-scale and large-scale companies. Acquisition of product portfolio of emerging players is a key strategy adopted by leading players for business expansion. Companies usually acquire R&D units of emerging players in order to co-develop innovative technologies. Mergers & acquisitions offer immense opportunities to companies in terms of financial leverage for production and commercialization of products.
  • Unmet needs in chronic inducible urticaria are creating significant opportunities for investors. Investment in R&D of cost-effective solutions is a key focus area of major companies. This is expected to boost the chronic inducible urticaria market in the next few years.

Leading companies operating in the global chronic inducible urticaria therapeutics market are:

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Celldex Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • BiosanaPharma BV
  • Gossamer Bio Inc
  • JHL Biotech Inc
  • Fountain Biopharma Inc
  • GI Innovation Co Ltd
  • Kolmar Korea Holdings Co Ltd
  • Mabtech Ltd
  • Mycenax Biotech Inc
  • PharmAbcine Inc

Global Chronic Inducible Urticaria Therapeutics Market: Research Scope

Global Chronic Inducible Urticaria Therapeutics Market, by Drug

  • 1st Generation Antihistamines
  • 2nd Generation Antihistamines
  • H2 Antagonists (Ranitidine and Cimetidine)
  • Leukotriene Receptor Antagonists
  • Corticosteroids
  • Cyclosporine A
  • Other Immunosuppressive Drugs
  • Other Drugs (Biologics)

Global Chronic Inducible Urticaria Therapeutics Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Oral

Global Chronic Inducible Urticaria Therapeutics Market, by Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

Global Chronic Inducible Urticaria Therapeutics Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
Chronic Inducible Urticaria Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Request Brochure

*Get Brochure (PDF) sent to your email within minutes

N/A

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

780

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved